A review of disease progression models of Parkinson's disease and applications in clinical trials

Novel Methods and Technologies for 21st-Century Clinical Trials

(2015) E. Ray Dorsey et al.   JAMA Neurology

The future is now: Model-based clinical trial design for Alzheimer's disease

(2015) K Romero et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout

(2014) Marcus A. Björnsson et al.   AAPS Journal

Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study

(2014) G. Reinoso et al.   EUROPEAN JOURNAL OF NEUROLOGY

Osteoarthritis disease progression model using six year follow-up data from the osteoarthritis initiative

(2014) Chaitali Passey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Levodopa: Effect on cell death and the natural history of Parkinson's disease

(2014) C. Warren Olanow   MOVEMENT DISORDERS

Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression

(2014) Robert Küffner et al.   NATURE BIOTECHNOLOGY

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

(2013) Jeffrey H. Kordower et al.   BRAIN

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

(2013) P A Milligan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development of a placebo effect model combined with a dropout model for bipolar disorder

(2013) Wan Sun et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

The Nature of Progression in Parkinson’s Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling

(2013) Lisa Kuramoto et al.   PLoS One

Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

(2012) Anushree Chatterjee et al.   ANTIVIRAL THERAPY

Progression of motor and nonmotor features of Parkinson's disease and their response to treatment

(2012) Thuy C. Vu et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes

(2012) Mahesh N. Samtani et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

(2012) James A. Rogers et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1

(2012) Jordan J. Elm et al.   MOVEMENT DISORDERS

Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development

(2011) Joo Yeon Lee et al.   AAPS Journal

An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative

(2011) Mahesh N. Samtani et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Interpreting the results of Parkinson's disease clinical trials: Time for a change

(2011) Nick H. G. Holford et al.   MOVEMENT DISORDERS

Motor complications in Parkinson's disease: Ten year follow-up study

(2010) Iria Cabo López et al.   MOVEMENT DISORDERS

Nonlinear decline of mini-mental state examination in Parkinson's disease

(2010) Dag Aarsland et al.   MOVEMENT DISORDERS

Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease

(2009) Venkatesh Atul Bhattaram et al.   AAPS Journal

Disease progression meta-analysis model in Alzheimer's disease

(2009) Kaori Ito et al.   Alzheimers & Dementia

Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study

(2009) R. Nandhagopal et al.   BRAIN

Progression of Parkinson's disease in the clinical phase: potential markers

(2009) Walter Maetzler et al.   LANCET NEUROLOGY

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

The FDA Critical Path Initiative and Its Influence on New Drug Development

(2008) Janet Woodcock et al.   Annual Review of Medicine

Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS